{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:01:24Z","timestamp":1772758884795,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ncl.2021.08.008","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T10:49:45Z","timestamp":1637146185000},"page":"113-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Diagnosis and Management of Central Nervous System Demyelinating Disorders"],"prefix":"10.1016","volume":"40","author":[{"given":"Lahoud","family":"Touma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Muccilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ncl.2021.08.008_bib1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1046\/j.1468-1331.2001.00299.x","article-title":"Hospitalization of patients with neurological disorders and estimation of the need of beds and of the related costs in Austria's non-profit hospitals","volume":"8","author":"Lampl","year":"2001","journal-title":"Eur J Neurol"},{"issue":"10","key":"10.1016\/j.ncl.2021.08.008_bib2","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1212\/WNL.0000000000000753","article-title":"Dramatically changing rates and reasons for hospitalization in multiple sclerosis","volume":"83","author":"Marrie","year":"2014","journal-title":"Neurology"},{"issue":"Pt 3","key":"10.1016\/j.ncl.2021.08.008_bib3","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/brain\/awl007","article-title":"Natural history of multiple sclerosis: a unifying concept","volume":"129","author":"Confavreux","year":"2006","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.ncl.2021.08.008_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2021.08.008_bib5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/jnnp.2008.157305","article-title":"The onset location of multiple sclerosis predicts the location of subsequent relapses","volume":"80","author":"Mowry","year":"2009","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2021.08.008_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jocn.2020.02.017","article-title":"Location of first attack predicts the site of subsequent relapses in multiple sclerosis","volume":"74","author":"Tsantes","year":"2020","journal-title":"J\u00a0Clin Neurosci"},{"issue":"7","key":"10.1016\/j.ncl.2021.08.008_bib7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archneur.63.7.1005","article-title":"Premenstrual multiple sclerosis pseudoexacerbations: role of body temperature and prevention with aspirin","volume":"63","author":"Wingerchuk","year":"2006","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2021.08.008_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-510X(94)00248-M","article-title":"Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential","volume":"129","author":"Guthrie","year":"1995","journal-title":"J\u00a0Neurol Sci"},{"issue":"6","key":"10.1016\/j.ncl.2021.08.008_bib9","first-page":"435","article-title":"Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials","volume":"247","author":"Brusaferri","year":"2000","journal-title":"J\u00a0Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2021.08.008_bib10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1468-1331.2000.00074.x","article-title":"Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis","volume":"7","author":"Sellebjerg","year":"2000","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ncl.2021.08.008_bib11","article-title":"Oral versus intravenous steroids for treatment of relapses in multiple sclerosis","volume":"12","author":"Burton","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"9056","key":"10.1016\/j.ncl.2021.08.008_bib12","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0140-6736(96)06453-7","article-title":"Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis","volume":"349","author":"Barnes","year":"1997","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ncl.2021.08.008_bib13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A\u00a0randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"9997","key":"10.1016\/j.ncl.2021.08.008_bib14","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0140-6736(15)61137-0","article-title":"Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial","volume":"386","author":"Le Page","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ncl.2021.08.008_bib15","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jamaneurol.2018.0024","article-title":"Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial","volume":"75","author":"Morrow","year":"2018","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2021.08.008_bib16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/1941874412458678","article-title":"Glucocorticoids: complications to anticipate and prevent","volume":"3","author":"Gensler","year":"2013","journal-title":"Neurohospitalist"},{"issue":"6","key":"10.1016\/j.ncl.2021.08.008_bib17","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A\u00a0randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2021.08.008_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","article-title":"Plasma exchange for severe attacks of CNS demyelination: predictors of response","volume":"58","author":"Keegan","year":"2002","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ncl.2021.08.008_bib19","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1212\/01.WNL.0000145798.61383.39","article-title":"IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS","volume":"63","author":"Sorensen","year":"2004","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ncl.2021.08.008_bib20","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1212\/01.WNL.0000128136.79044.D6","article-title":"Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects","volume":"62","author":"O'Connor","year":"2004","journal-title":"Neurology"},{"issue":"Pt 7","key":"10.1016\/j.ncl.2021.08.008_bib21","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awn098","article-title":"Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis","volume":"131","author":"Lucchinetti","year":"2008","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.ncl.2021.08.008_bib22","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1177\/1352458512438237","article-title":"Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study","volume":"18","author":"Altintas","year":"2012","journal-title":"Mult Scler"},{"issue":"7","key":"10.1016\/j.ncl.2021.08.008_bib23","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archneurol.2011.34","article-title":"Beneficial plasma exchange response in central nervous system inflammatory demyelination","volume":"68","author":"Maga\u00f1a","year":"2011","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2021.08.008_bib24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S1474-4422(14)70052-3","article-title":"Bal\u00f3's concentric sclerosis","volume":"13","author":"Hardy","year":"2014","journal-title":"Lancet Neurol"},{"issue":"13","key":"10.1016\/j.ncl.2021.08.008_bib25","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2169\/internalmedicine.52.9330","article-title":"Anti-aquaporin-4 antibody-seronegative NMO spectrum disorder with Bal\u00f3's concentric lesions","volume":"52","author":"Masuda","year":"2013","journal-title":"Intern Med"},{"issue":"4","key":"10.1016\/j.ncl.2021.08.008_bib26","first-page":"491","article-title":"A\u00a0case of primary form of progressive multifocal leukoencephalopathy with concentric demyelination of Bal\u00f3 type","volume":"15","author":"Markiewicz","year":"1977","journal-title":"Neuropatol Pol"},{"issue":"1","key":"10.1016\/j.ncl.2021.08.008_bib27","first-page":"1","article-title":"MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain : a review of reported findings","volume":"255","author":"Seewann","year":"2008","journal-title":"J\u00a0Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2021.08.008_bib28","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1177\/1352458511400475","article-title":"Astrocytopathy in Balo's disease","volume":"17","author":"Kira","year":"2011","journal-title":"Mult Scler"},{"issue":"9","key":"10.1016\/j.ncl.2021.08.008_bib29","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1474-4422(16)30043-6","article-title":"Atypical inflammatory demyelinating syndromes of the CNS","volume":"15","author":"Hardy","year":"2016","journal-title":"Lancet Neurol"},{"issue":"Suppl 4","key":"10.1016\/j.ncl.2021.08.008_bib30","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.1007\/s10072-004-0341-1","article-title":"Marburg type and Bal\u00f2's concentric sclerosis: rare and acute variants of multiple sclerosis","volume":"25","author":"Capello","year":"2004","journal-title":"Neurol Sci"},{"issue":"1","key":"10.1016\/j.ncl.2021.08.008_bib31","first-page":"107","article-title":"Schilder's myelinoclastic diffuse sclerosis","volume":"77","author":"Poser","year":"1986","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.ncl.2021.08.008_bib32","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/archneur.64.10.1426","article-title":"Acute fulminant demyelinating disease: a descriptive study of 60 patients","volume":"64","author":"de Seze","year":"2007","journal-title":"Arch Neurol"},{"issue":"16 Suppl 2","key":"10.1016\/j.ncl.2021.08.008_bib33","first-page":"S7","article-title":"Consensus definitions proposed for pediatric multiple sclerosis and related disorders","volume":"68","author":"Krupp","year":"2007","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.ncl.2021.08.008_bib34","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1212\/WNL.59.8.1224","article-title":"Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients","volume":"59","author":"Tenembaum","year":"2002","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ncl.2021.08.008_bib35","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1212\/WNL.56.10.1313","article-title":"Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients","volume":"56","author":"Schwarz","year":"2001","journal-title":"Neurology"},{"issue":"9 Suppl 2","key":"10.1016\/j.ncl.2021.08.008_bib36","first-page":"S38","article-title":"Acute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome","volume":"87","author":"Pohl","year":"2016","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.ncl.2021.08.008_bib37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jneuroim.2008.06.004","article-title":"Oligoclonal IgG band patterns in inflammatory demyelinating human and mouse diseases","volume":"200","author":"Franciotta","year":"2008","journal-title":"J\u00a0Neuroimmunol"},{"issue":"22","key":"10.1016\/j.ncl.2021.08.008_bib38","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1212\/WNL.0000000000002723","article-title":"Acute disseminated encephalomyelitis in 228 patients: A retrospective, multicenter US study","volume":"86","author":"Koelman","year":"2016","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ncl.2021.08.008_bib39","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJM198702123160703","article-title":"Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination","volume":"316","author":"Hemachudha","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ncl.2021.08.008_bib40","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/archneur.62.4.650","article-title":"Acute disseminated encephalomyelitis after liver transplantation","volume":"62","author":"Lindzen","year":"2005","journal-title":"Arch Neurol"},{"issue":"11","key":"10.1016\/j.ncl.2021.08.008_bib41","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"issue":"14","key":"10.1016\/j.ncl.2021.08.008_bib42","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1177\/1352458516631038","article-title":"Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases","volume":"22","author":"Baumann","year":"2016","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.ncl.2021.08.008_bib43","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.ncl.2021.08.008_bib44","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/archneur.62.11.1673","article-title":"Acute disseminated encephalomyelitis: an update","volume":"62","author":"Menge","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2021.08.008_bib45","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3389\/fneur.2020.00899","article-title":"Acute hemorrhagic leukoencephalitis: a case and systematic review of the literature","volume":"11","author":"Grzonka","year":"2020","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2021.08.008_bib46","first-page":"351","article-title":"Eug\u00e8ne Devic (1858-1930)","volume":"249","author":"Miyazawa","year":"2002","journal-title":"J\u00a0Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2021.08.008_bib47","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2021.08.008_bib48","article-title":"Bright spotty lesions as an imaging marker for neuromyelitis optica spectrum disorder","volume":"26","author":"Salama","year":"2021","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.ncl.2021.08.008_bib49","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","article-title":"Brain abnormalities in neuromyelitis optica","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2021.08.008_bib50","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ncl.2021.08.008_bib51","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/archneur.65.5.629","article-title":"Aquaporin-4 autoantibodies in a paraneoplastic context","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2021.08.008_bib52","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.ncl.2021.08.008_bib53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"10.1016\/j.ncl.2021.08.008_bib54","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2021.08.008_bib55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ncl.2021.08.008_bib56","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ncl.2021.08.008_bib57","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jnnp-2020-325121","article-title":"Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MSJournal of Neurology","volume":"92","author":"Banks","year":"2021","journal-title":"Neurosurgery & Psychiatry"},{"issue":"9","key":"10.1016\/j.ncl.2021.08.008_bib58","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861921000803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861921000803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:20:06Z","timestamp":1760005206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861921000803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0733861921000803"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2021.08.008","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Management of Central Nervous System Demyelinating Disorders","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2021.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}